Linoleic Acid-Menthyl Ester Reduces the Secretion of Apolipoprotein B100 in HepG2 Cells

被引：3

作者：

Inoue, Nao ^{[1
]}

Yamano, Naomi ^{[1
]}

Sakata, Kotaro ^{[1
]}

Arao, Keisuke ^{[2
]}

Kobayashi, Takashi ^{[3
]}

Naga, Toshihiro ^{[4
]}

Shimada, Yuji ^{[4
]}

Nagao, Koji ^{[1
]}

Yanagita, Teruyoshi ^{[1
]}

机构：

[1] Saga Univ, Dept Appl Biochem & Food Sci, Saga 8408502, Japan

[2] Nishikyushu Univ, Dept Hlth & Nutr Sci, Kanzaki 8428585, Japan

[3] Kyoto Univ, Div Food Sci & Biotechnol, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan

[4] Osaka Municipal Tech Res Inst, Biomat & Commod Chem Res Div, Osaka 5368553, Japan

来源：

JOURNAL OF OLEO SCIENCE | 2009年 / 58卷 / 04期

关键词：

linoleic acid-menthyl ester; apolipoprotein B100; apolipoprotein A-1; HepG2; cells; ASCORBYL PALMITATE; INHIBITION; LIPIDS;

D O I：

10.5650/jos.58.171

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

The effect of linoleic acid-menthyl ester (LAME) on lipid metabolism were assessed in HepG2 cells. It is well known that high level of apolipoprotein (apo) B100 in the serum is risk for atherosclerosis. Although linoleic acid (LA) treatment and LA plus L-mentol treatment increased apo B100 secretion, LAME treatment significantly decreased apo B100 secretion in HepG2 cells compared with control medium. The hypolipidemic effect of LAME was attributable to the suppression of triglyceride synthesis in HepG2 cells. It is also known that the risk of coronary heart disease is negatively related to the concentration of serum apo A-L In the present study, LAME treatment increased apo A-1 secretion as compared with LA treatment in HepG2 cells. These results suggest that mentyl-esterification of fatty acids may be beneficial in anti-atherogenic dietary therapy.

引用

页码：171 / 175

页数：5

共 50 条

[41] Riboflavin deficiency impairs oxidative folding and secretion of apolipoprotein B-100 in HepG2 cells, triggering stress response systems
Manthey, KC
Chew, YC
Zempleni, J
JOURNAL OF NUTRITION, 2005, 135 (05): : 978 - 982
[42] Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion?
Meex, Steven J. R.
Andreo, Ursula
Sparks, Janet D.
Fisher, Edward A.
JOURNAL OF LIPID RESEARCH, 2011, 52 (01) : 152 - 158
[43] Lipid aldehyde-mediated cross-linking of apolipoprotein B-100 inhibits secretion from HepG2 cells
Stewart, Benjamin J.
Roede, James R.
Doorn, Jonathan A.
Petersen, Dennis R.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2009, 1791 (08): : 772 - 780
[44] OLEIC-ACID STIMULATION OF APOLIPOPROTEIN-B SECRETION FROM HEPG2 AND CACO-2 CELLS OCCURS POSTTRANSCRIPTIONALLY
MOBERLY, JB
COLE, TG
ALPERS, DH
SCHONFELD, G
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1042 (01) : 70 - 80
[45] Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells
Zhu, DM
Ganji, SH
Kamanna, VS
Kashyap, ML
ATHEROSCLEROSIS, 2002, 164 (02) : 221 - 228
[46] Use of cyclodextrin to deliver lipids and to modulate apolipoprotein B-100 production in HepG2 cells
Peluso, MR
Dixon, JL
LIPIDS, 1997, 32 (08) : 811 - 823
[47] AN INHIBITOR OF SQUALENE EPOXIDASE, NB-598, SUPPRESSES THE SECRETION OF CHOLESTEROL AND TRIACYLGLYCEROL AND SIMULTANEOUSLY REDUCES APOLIPOPROTEIN-B IN HEPG2 CELLS
HORIE, M
HAYASHI, M
SATOH, T
HOTTA, H
NAGATA, Y
ISHIDA, F
KAMEI, T
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1168 (01) : 45 - 51
[48] Tunicamycin induces ubiquitination and degradation of apolipoprotein B in HepG2 cells
Liao, W
Chan, L
BIOCHEMICAL JOURNAL, 2001, 353 : 493 - 501
[49] THE APOLIPOPROTEIN (APO)-B GENE IS CONSTITUTIVELY EXPRESSED IN HEPG2 CELLS
PULLINGER, CR
NORTH, JD
MEDINA, P
TENG, BB
RIFICI, VA
DEBRITO, AER
SCOTT, J
ARTERIOSCLEROSIS, 1988, 8 (05): : A564 - A564
[50] Inhibition of acyl-CoA:cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells
Musanti, R
Giorgini, L
Lovisolo, P
Pirillo, A
Chiari, A
Ghiselli, G
JOURNAL OF LIPID RESEARCH, 1996, 37 (01) : 1 - 14

← 1 2 3 4 5 →